Goldman Sachs Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $45
Portfolio Pulse from richadhand@benzinga.com
Goldman Sachs analyst Graig Suvannavejh has downgraded Halozyme Therapeutics from Buy to Neutral, while raising the price target from $43 to $45.

July 24, 2023 | 8:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Halozyme Therapeutics has been downgraded from Buy to Neutral by Goldman Sachs, but the price target has been raised from $43 to $45.
The downgrade from Buy to Neutral indicates a less optimistic outlook for the stock, which could potentially lead to a decrease in demand and thus a decrease in the stock price. However, the increase in the price target from $43 to $45 suggests that the analyst still sees potential for the stock's price to increase, which could counteract the potential negative impact of the downgrade.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100